TECTONIC THERAPEUTIC, INC. Impairment of Long-Lived Assets Held-for-use
TECTONIC THERAPEUTIC, INC. (TECX) reported Impairment of Long-Lived Assets Held-for-use of $940.00 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2024-05-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2024-05-09
- TECTONIC THERAPEUTIC, INC. impairment of long-lived assets held-for-use for the quarter ending 2023-09-30 was $940.00K.
- TECTONIC THERAPEUTIC, INC. impairment of long-lived assets held-for-use for the quarter ending 2018-12-31 was $0.00.
- TECTONIC THERAPEUTIC, INC. impairment of long-lived assets held-for-use for the quarter ending 2018-09-30 was $0.00.
- TECTONIC THERAPEUTIC, INC. impairment of long-lived assets held-for-use for the quarter ending 2018-06-30 was $0.00.
- TECTONIC THERAPEUTIC, INC. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
- TECTONIC THERAPEUTIC, INC. impairment of long-lived assets held-for-use for fiscal 2021 was $0.00.
- TECTONIC THERAPEUTIC, INC. impairment of long-lived assets held-for-use for fiscal 2020 was $0.00.
- TECTONIC THERAPEUTIC, INC. impairment of long-lived assets held-for-use for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|
| 2023-09-30 | $940.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $0.00 10-K · filed 2023-03-23 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-23 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-17 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-18 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $0.00 derived: sum of 2 quarters · filed 2020-03-16 | $0.00 derived: sum of 3 quarters · filed 2020-03-16 | $235.00K 10-K · filed 2020-03-16 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $235.00K 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $235.00K 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $235.00K 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |